3-氮杂双环[2.2.2]辛烷盐酸盐 | 5845-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-氮杂双环[2.2.2]辛烷盐酸盐
• 中文别名: 2-氮杂双环[2.2.2]辛烷盐酸盐
• 英文名称: 2-azabicyclo-[2.2.2.]octane hydrochloride
• 英文别名: isoquinuclidine hydrochloride；2-Azabicyclo[2.2.2]octane hydrochloride；2-azabicyclo[2.2.2]octane;hydrochloride
• CAS: 5845-15-8
• 化学式: C₇H₁₃N*ClH
• mdl: MFCD19159806
• 分子量: 147.648
• InChiKey: HPKXYVYKZCJKIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.05
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，惰性气体

反应信息

• 作为反应物：
  描述：

  3-氮杂双环[2.2.2]辛烷盐酸盐 在 palladium dihydroxide 、 偶氮二甲酸二乙酯 咪唑 、 4-二甲氨基吡啶 、 Zn(N₃)₂*Py₂ 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气 、 potassium carbonate 、 三乙胺 、 三苯基膦 作用下， 以 乙醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 20.0 ℃ 、344.74 kPa 条件下， 反应 111.0h， 生成 (S)-1-(2-Azabicyclo[2.2.2]oct-2-yl)-2-[3-(2-amino-1-methylethyl)-2-(3,5-dimethylphenyl)-1H-1-(tert-butoxycarbonyl)-pyrrolo[2,3-b]-pyridin-5-yl]-2-methylpropan-1-one
  参考文献：
  名称：

  6和7氮杂吲哚衍生的GnRH拮抗剂的总合成

  摘要：

  钯（0）催化的三乙基甲硅烷基炔烃和邻氨基氨基碘吡啶衍生物的杂环化反应是高度收敛到具有生物意义的6-和7-氮杂吲哚的关键步骤。

  DOI：

  10.1016/s0040-4039(01)01322-3
• 作为产物：
  描述：

  4-氨基环己羧酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 3-氮杂双环[2.2.2]辛烷盐酸盐
  参考文献：
  名称：

  Isoquinuclidine-based expectorants. Synthesis and biological activities of N-alkoxybenzylisoquinuclidines

  摘要：

  N-Di-, trialkoxybenzylisoquinuclidines and related compounds were synthesized and evaluated for expectorant activities. Structure-activity relationship investigations in this series showed that both the trialkoxyphenyl ring and the basic nitrogen atom at the benzylic position were necessary for activity. N-Trialkoxybenzylisoquinuclidines 7a, 7c, 7d, 7f and 7g significantly increased bronchial secretion, and ethoxy derivative 7c showed the highest activity in these compounds. The n-propyloxy derivatives 7d and 7f also accelerated bronchoalveolar surfactant secretion with about two to four times more activity than ambroxol (7d and 7f; ED50 = 27.5 and 15.5 mg/kg po, respectively); however, compounds 7a, 7c and 7g were less active than ambroxol. Compounds 7d and 7f were selected for further examination. These compounds displayed antioxidant activity in vitro (7d and 7f, IC50 = 48.0 and 66.0 mu M, respectively). Compound 7d also showed inhibition on bradykinin- or antigen-induced airway inflammation in guinea pigs. These findings suggest that compounds 7d and 7f are potent expectorants with antiinflammatory activity.

  DOI：

  10.1016/s0223-5234(97)81675-3

文献信息

• [EN] 6H-THIENO`2, 3-B!PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)<br/>[FR] DERIVES DE 6H-THIENO`2,3-B!PYRROLE EN TANT QU'ANTAGONISTES DE LA GONADOLIBERINE (GNRH)
  申请人：ASTRAZENECA AB

  公开号：WO2004018480A1

  公开（公告）日：2004-03-04

  The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

  这项发明涉及一组新型噻吩-吡咯烷化合物的化学式（I）：其中：R1、R2、R3、R4和R5如规范中定义，这些化合物可用作促性腺激素释放激素拮抗剂。该发明还涉及所述化合物的药物配方、使用所述化合物的治疗方法以及所述化合物的制备方法。
• Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them
  申请人：Genevois-Borella Arielle

  公开号：US20050165005A1

  公开（公告）日：2005-07-28

  The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH 2 , ORc, SRc, SORa, SO 2 Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSO 2 Ra, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF 3 , CHF 2 , CH 2 F, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.

  本发明涉及公式(I)的新颖衍生物，其中A是，如果存在的话，(C1-C6)烷基，(C3-C6)烯基，(C3-C6)炔基，(C3-C7)环烷基或(C5-C7)环烯基，R1是NR6R7，(C4-C7)氮杂环烷基，(C5-C7)氮杂环烯基，(C5-C9)氮杂双环烷基或(C5-C9)氮杂双环烯基；A-R1是这样的，即R1的氮原子和吡唑的1位的氮原子之间至少被两个碳原子分隔，R3是H，卤素，OH，SH，NH2，ORc，SRc，SORa，SO2Ra，NHCHO，NRaRb，NHC(O)Ra，NHC(S)Ra或NHSO2Ra，R4是芳基或杂芳基；R5是H，卤素，CF3，CHF2，CH2F，直链或支链(C1-C6)烷基或(C3-C7)环烷基，它们的外消旋体、对映体和非对映异构体，以及它们的混合物，它们的互变异构体和它们的药学上可接受的盐。
• ISOQUINUCLIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：Kotobuki Pharmaceutical Co., Ltd.

  公开号：EP1375500A1

  公开（公告）日：2004-01-02

  An isoquinuclidine derivative represented by the following general formula (I): (I) [wherein A1 is methylene or carbonyl]: R1 is hydrogen or methyl: R2 is -(CH2)n-A2-Ph (n is an integer of 0 to 3 and A2 is a single bond or -O-): and R3 is -COOH, -COOR4, -COSR4 (R4 is lower alkyl, unsubstituted phenyl, or phenyl substituted by a lower alkyl, lower alkoxy, hydroxyl, methoxycarbonyl, ethoxycarbonyl, or trifluoromethanesulfonamide group or by a halogen atom), etc.] or a pharmaceutically acceptable salt of the compound. Also provided is an oral remedy for diabetes, which contains the compound and has hypoglycemic activity.

  一种由以下一般式（I）表示的异喹啉衍生物：（I）[其中A1为亚甲基或羰基]：R1为氢或甲基；R2为-(CH2)n-A2-Ph（n为0至3的整数，A2为单键或-O-）；R3为-COOH，-COOR4，-COSR4（R4为低碳基，未取代的苯基，或由低碳基，低氧基，羟基，甲氧羰基，乙氧羰基或三氟甲磺酰胺基团或卤原子取代的苯基）等]或该化合物的药用盐。还提供了一种口服糖尿病治疗药物，含有该化合物并具有降血糖活性。
• Process for the preparation of tertiary amines
  申请人：G. D. Searle & Co.

  公开号：US04086234A1

  公开（公告）日：1978-04-25

  Certain tertiary amines useful as pharmaceuticals are prepared in improved yields by condensing a cyclic secondary amine with a primary alkyl halide in an aqueous medium in the presence of an acid acceptor.

  某些作为药物有用的三级胺，通过在水性介质中在酸受体的存在下，将环状二级胺与一级烷基卤化物缩合，以提高产量制备。
• [EN] CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2,4-DIOXOPYRIMIDINE INHIBANT CD73
  申请人：GILEAD SCIENCES INC

  公开号：WO2021222522A1

  公开（公告）日：2021-11-04

  The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

  本公开提供了嘧啶二酮类化合物及其药物组合物，用于治疗癌症，包括实体肿瘤。这些化合物可以单独使用或与其他抗癌药物联合使用。